Neuroendocrine neoplasms (NENs) are heterogeneous tumors originating from neuroendocrine cells. Their malignant potential varies from indolence to high-grade malignancy (carcinomas). We studied the survival of all NENs in Norway according to malignant potential and different primary sites. We identified all NEN cases diagnosed in 1993 to 2015 and reported to the national population-based Cancer Registry of Norway. We included 62 morphological types. According to morphological characteristics and known disease behavior, we stratified the tumors into two different groups: low/intermediate aggressiveness and high aggressiveness. A total of 17,128 NENs were analyzed. Median age was 67 years and 47.6% were females. The most common primary sites were in the lungs and the gastroenteropancreatic (GEP) system. The 5-year relative survival in patients with low/intermediate aggressive NENs was 64.8% (95% CI, 63.3-66.2) and high aggressive NENs 8.4% (95% CI, 7.8-9.1). Females had higher survival rates than males (p <0.001). The relative 5-year survival rate in patients younger than 50 years was 89.1% (95% CI, 87.4-90.7) vs 41.0% (95% CI, 34.9-46.9) in patients 80 years. In multivariable analysis gender, age at diagnosis, time of diagnosis, stage and primary sites were all predictors of outcome both in patients with low/intermediate tumors and high aggressive tumors. Survival improved significantly over time, regardless of sex, age and tumor stage.
Introduction
Neuroendocrine neoplasms (NENs) are a heterogeneous group of tumors that may arise in most organs. They can cause clinical syndromes due to production of peptides and neuroamines. The malignant potential varies from slow growing indolent tumors to highly aggressive carcinomas. The incidence is increasing, 1 and there is an ongoing discussion whether this increase is real or due to incidental findings, more extensive use of radiological and endoscopic procedures, or changes in classification. Most published studies report survival in gastroenteropancreatic (GEP) and lung NENs. We know less about neoplasms originating from rare sites and the highly aggressive carcinomas. Among the epidemiological studies, there are few reports on trends in survival. New therapeutic strategies, such as mammalian target of rapamycin (m-TOR) inhibitors and peptide receptor radionuclide therapy (PRRT) have been evolving the last decade. These new treatment modalities, together with handling of these patients in multidisciplinary teams, are believed to improve survival.
The aim of our study was to investigate survival in all types of NENs from all primary sites diagnosed in Norway from 1993 through 2015. We also wanted to investigate changes in survival during our study period.
Materials and Methods
We identified all NEN cases diagnosed between 1993 through 2015 that were reported to the Cancer Registry of Norway (CRN). CRN was established in 1953 and covers the entire Norwegian population (5.2 million in 2016 of whom 95% is Caucasians). All inhabitants are given a unique 11-digit personal identification number (at time of birth or immigration) that ensures unequivocal identification. Data from CRN is linked to the Norwegian Population Register to obtain dates of death. CRN coding is performed by trained personnel based on reports from several different sources such as clinician reports, pathology and autopsy reports and death certificates. 2 All medical doctors are mandated by law to report all new cancer cases as well as benign and premalignant neoplasms of the central nervous system. The degree of completeness is estimated to be 98.8%. Stage at the time of diagnosis was categorized as localized disease, regional disease and distant disease based on the aggregation of 10 CRN categories of disease dissemination. No disease spread is categorized as localized disease. Regional disease is per definition when tumor grows microscopically or macroscopically into a neighboring structure or lymph nodes of the same body segment as the primary tumor. Distant disease includes metastases to lymph nodes or organs in a body segment other than that of the primary tumor. Stage was missing for 12.2% of the cases. To handle the problem of missing stage multiple imputation was used. Stage was imputed using a multinomial logistic regression where sex, age at diagnosis, period of diagnosis, aggressiveness, primary localization and the outcome indicator (dead/censored) were included as categorical variables, and where the time to event or censoring was included as a continuous variable. We created 50 datasets with imputed values of stage and all analyses were conducted on these datasets, combining the results using Rubin's rules. 18 Relative survival was estimated using the consistent nonparametric estimator proposed by Pohar-Perme et al.
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Throughout this article, the term relative survival is used to avoid the potential confusion added by using the more precise term, net survival. Relative survival is defined as the ratio of the proportion of observed survivors in a cohort of cancer patients to the proportion of expected survivors in a comparable set of cancer free individuals. To examine which prognostic factors that would affect cancer survival, a flexible parametric proportional excess hazard model 20 was estimated with sex, period of diagnosis, age at diagnosis, disease stage and primary site (grouped into 8 categories; lung, stomach, small intestine, colon/rectum, appendix, pancreas, adrenal gland and all others) included as independent categorical variables. The model was also estimated separately for low/intermediate and high aggressive NENs. The baseline cumulative excess hazard was modelled using restricted cubic splines with three internal knots placed at the quartiles of the distribution of the log of the uncensored survival times. The statistical analyses were performed using Stata 14.2.
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Results
We included a total of 17,128 patients diagnosed with NEN from 1993 through 2015. Median age was 67 years and 47.6% were females. The stage was localized in 21.8%, regional in 20.8%, distant in 45.1% and unknown in 12.2% of the patients. Among patients with tumors of low/intermediate aggressiveness, the most frequent primary sites were the small intestine (19%), the lungs (17%), and the appendix (12%). Tumors of high aggressiveness, the carcinomas, occurred most frequently in the lungs (88%) and there was almost none in the small intestine (n 5 4) and the appendix (n 5 0). Tumor characteristics are presented in Table 2 .
The 5-year relative survival in patients with low/intermediate aggressive NENs was 64.8% (95% CI, 63.3-66.2) and high aggressive NENs 8.4% (95% CI, 7.8-9.1). Estimated relative survival (1-, 5-and 10-year) according to primary site, stage and aggressiveness are presented in detail in Table 3 . (Fig.1a) . The difference was also significant for 1-and 10-year relative survival rates. For patients with low/intermediate aggressive tumors there were significant gender differences in stage distribution. For females, the percentages of patients with localized and distant disease were 50 and 30, and for males 39 and 40, respectively. Even after adjusting for these differences, males had poorer prognosis (Table 4) . There were no gender differences in stage distribution in the high aggressiveness group.
We also studied survival in different age groups (0-49, 50-59, 60-69, 70-79 and 80 years). For patients with low/ intermediate aggressive tumors, there was a significant fall in relative survival with increasing age (Fig. 1b) . The 5-year relative survival rate in patients younger than 50 years was 89.1% (95% CI, 87.4-90.7) vs 41.0% (95% CI, 34.9-46.9) in patients 80 years. There were relatively more patients with localized disease in the youngest age group compared to the older age groups. In the youngest age group, 68% had localized disease and 13% had distant disease. In the older age groups, 32-42% had localized disease and 37-43% had distant disease. The falling survival with increasing age was still significant after adjusting for stage (Table 4) . This difference in survival with increasing age was found for all primary sites In primary sites with few cases and percent <1, only the number of cases is given. Abbreviations: N, number of patients (in addition to this number, cases of unknown stage are included by imputation); yr, year.
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(Supporting Information Fig. S1 ).We found the same differences in survival between age groups for patients with highly aggressive tumors. In the youngest age group, the 5-year relative survival rate was 17.2% (95% CI, 13.9-20.9) vs 8.0% (95% CI, 5.7-10.7) in the oldest age group. For patients with highly aggressive tumors, there was no difference in stage distribution between age groups. Details regarding age distribution according to primary sites and aggressiveness can be found in supplement (Supporting Information Table S1 ).
To examine changes in relative survival over time, we divided the study period in three, 1993 to 2000, 2001 to 2007 and 2008 to 2015. In univariable analyses, there were no significant differences in the low/intermediate aggressiveness groups over time, but significant improvement in relative survival in patients with highly aggressive tumors (Fig.  1c) . The 5-year relative survival estimates in the latter group were 5.9% (95% CI, 5.0-6.9), 7.9% (95% CI, 6.9-9.0) and 11.3% (95% CI, 10.1-12.7), respectively. In multivariable analysis, however, we found an improvement in relative survival also in the low/intermediate aggressiveness group (Table 4) . To investigate further if the change in survival was different in any subgroups, we conducted multivariable analyses stratified on stage (Supporting Information Table  S2 ), gender and age groups. We found significant improvement in relative survival after year 2000 in all stages, genders and age groups. There was also a trend towards better survival in 2008-2015 compared to 2001-2007, but this was non-significant.
In both univariable and multivariable analyses, the survival was best for patient with localized disease and worst for patients with distant disease (Fig. 2, Table 4 ). Figure 2a shows relative survival up to 10 years, according to stage in the most common primary sites in low/intermediate aggressive tumors. Patients with small intestinal NENs had the highest relative survival rate in distant disease, while they had among the poorest relative survival rates in localized disease. In advanced disease, patients with primary site in the lungs, had the lowest 5-year relative survival compared to other common primary sites. Figure 2b shows relative survival in highly aggressive NENs up to 10 years. In tumors with high aggressiveness, the survival was lowest for the lung carcinomas in local and regional disease. In distant disease, the survival in lung carcinomas was similar to survival in carcinomas of the GEP system, but lower than survival in skin carcinomas (Merkel cell carcinomas). The results from the multiply imputed analyses were compared to results obtained from complete cases analyses (data not shown). Estimates were very similar and the conclusions remained unaltered. Abbreviations: CI, confidence interval. * Not analyzed due to few cases.
Discussion
Our analysis of survival in all NEN patients in Norway from 1993 through 2015 is one of the most comprehensive reports on NEN survival up to date. We found that females, younger age, diagnosis after year 2000 and localized disease were all associated with a better prognosis. Primary site in the lungs has a poor prognosis compared to localization in the GEP system. Within the GEP system in low/intermediate aggressive tumors, the relative survival was best for primary sites in the small intestine and the appendix, while the worst prognosis was found for primary sites in the stomach, colon/rectum and pancreas. The relative survival rates differed according to primary sites, and were consistent with previously published population-based studies. [22] [23] [24] [25] included atypical carcinoids, and still showed higher survival rates than in our study. This finding can be caused by differences in registration practice, but may also be indicative of geographical differences. In our analyses, patients with low/ intermediate aggressive pancreatic NENs had higher survival rates than previously has been reported. 22, [24] [25] [26] This might be due to the inclusion of all pancreatic NENs in our study, even small insulinomas with a good prognosis. Other registries record these NENs only after they have metastasized and thus fulfill the requirements to be categorized as malignant according to ICD-O.
As expected, the effect of tumor aggressiveness and stage was both highly significant and clinically relevant for the survival. More interestingly, gender was an important predictor of outcome. This confirms the finding in previous epidemiological studies. 23, 26 There was a difference in stage distribution Cancer Epidemiology among males and females, but even after adjusting for these differences males had 31% higher mortality than females in low/intermediate aggressive tumors, and 11% higher mortality in highly aggressive tumors. This might indicate different tumor biology and the need of more aggressive treatment approaches in males. The difference could also, at least partly, be explained by a different health-care seeking behavior among men compared to women. Men might endure symptoms for a longer period than women before contacting the health services, and hence, presenting with a higher tumor burden and a less favorable prognosis. 27 In the low/intermediate and high aggressiveness groups, we found age to be a significant predictor of outcome in both univariable and multivariable analyses with decreasing relative survival rates with increasing age. This age effect has also been supported by reports from the SEER data 23, 28 who categorized their patients into three age groups (30, 31-60 and >60 years) and found better survival in the youngest patients. We know that younger patients may tolerate treatments such as extensive surgery and chemotherapy better and might receive, and endure, more aggressive treatment modalities than older patients. This could explain at least some of the differences in the high aggressiveness group where heavy chemotherapy is the mainstay of the palliative treatment. We do not believe, however, that tolerance to therapy could be important in explaining the differences in survival in the low/intermediate aggressiveness group as most of the treatments offered to this group are well tolerated across age groups. Our study design is not suitable to explore etiological factors, but our findings might indicate different tumor biology and genetic alterations in different age groups.
There In some situations, the survival of NEN-patients might exceed the expected survival in the comparable population, and thus relative survival will increase. In cases with few patients this increase will be mainly due to statistical uncertainty. Abbreviation: GEP, Gastroenteropancreatic.
improved survival could, however, also be related to lead time bias. The use and quality of radiological and endoscopic procedures have increased substantially 1 and it is possible that NENs are diagnosed earlier giving an improved survival due to earlier diagnosis without prolonging life.
The strength of our study is the completeness of data. Close to 100% of all cases of cancer detected in Norway are reported to the Cancer Registry of Norway. In contrast, the SEER database covers only 28% of the US population. 31 The unique identification number that is given to all inhabitants in Norway ensures that no patients, except migrants, are lost to follow-up due to change of address or place of treatment.
One of the limitations of this study is that the population of Norway is rather small (5.2 million) reducing the power of some of the estimates related to this group of rather rare neoplasms. The stratification of neoplasms into different tumor aggressiveness groups is, as for other epidemiological studies, hampered with weaknesses. Ki-67% was not done in most cases and could not be used for stratification. The stratification was therefore based on the morphological characteristics reported in the pathology report and known disease behavior of the actual neoplasm. This stratification was consequently based upon the quality of the individual pathology reports. Some degree of misclassification may have occurred, probably slightly underestimating the survival in the low/intermediate group and slightly overestimating the survival in the high aggressiveness group.
Conclusion
In our study, gender, age at diagnosis, period of diagnosis, tumor aggressiveness, stage and primary site were all significant predictors of outcome. Men have a poorer prognosis than women do, regardless of their tumor stage or aggressiveness. The survival has improved in all stages and age groups during our study period.
